For example, both the Janus kinase 3 inhibitor tofacitinib, which decreases the number of CD16/56+ NK cells, and the tumor necrosis factor (TNF)-α inhibitor etanercept are widely used for clinical RA therapy (Zhao et al., 2018). The gene discussed is JAK3; the disease is rheumatoid arthritis.